Evaluation of AZD2171, an oral, highly potent and selective VEGFR signaling inhibitor, in renal cell carcinoma (RCC): Combined results from two phase I studiesC. van Herpen, Giuseppe Giaccone, Hester van Cruijsen et al.|Journal of Clinical Oncology|2007Cited by 10